

IAP4 Rec'd PGT/PTO 03 JAN 2006

hereby certify that this correspondence is being  
deposited with the United States Postal Service as  
first class mail in an envelope addressed to:

Commissioner for Patents, P.O. Box 1450

Alexandria, VA 22313 on December 27, 2005

David Saliwanchik

David R. Saliwanchik, Patent Attorney

INFORMATION DISCLOSURE  
STATEMENT

Examining Group *not yet assigned*

Patent Application

Docket No. BB-156

Serial No. 10/551,658

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : Not yet assigned  
Art Unit : Not yet assigned  
Applicants : Michael Gotthardt, Michael Radke  
Serial No. : 10/551,658  
Filed : September 30, 2005  
For : Inducible Site-Directed Mutagenesis through Conditional Gene  
Rescue

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313

INFORMATION DISCLOSURE STATEMENT  
UNDER 37 CFR §§1.97 AND 1.98

Sir:


The above-identified patent application was filed in the U.S. Patent Office as a national application under 35 USC §371. A copy of the International Search Report and copies of the references cited therein have been made available in the national stage file.

However, for the examiner's convenience, the applicants are attaching a copy of the International Search Report as well as copies of the documents cited in the International Search Report. Also attached is Form PTO/SB/08 listing the references. Applicants have not submitted a copy of the U.S. patent cited on attached Form PTO/SB/08 pursuant to 37 CFR 1.98(a)(2)(ii).

In accordance with 37 CFR §1.56, the applicants hereby request that the references cited in the International Search Report and listed on the attached form PTO/SB/08 be made of record and considered in the examination of the subject application. If any additional fee is required, or to credit any overpayment, please use Deposit Account No. 19-0065.

Applicants respectfully assert that the substantive provisions of 37 CFR §§1.97 and 1.98 are met by the foregoing statement.


Respectfully submitted,



David R. Saliwanchik  
Patent Attorney  
Registration No. 31,794  
Phone No.: 352-375-8100  
Fax No.: 352-372-5800  
Address: P.O. Box 142950  
Gainesville, FL 32614-2950

DRS/hey

Attachments: Form PTO/SB/08;  
Copy of International Search Report; and  
Copies of cited references.



PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>Substitute for form 1449A/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/551,658
				Filing Date	September 30, 2005
				First Named Inventor	Michael Gotthardt
				Art Unit	Not yet assigned
				Examiner Name	Not yet assigned
Sheet	1	of	2	Attorney Docket Number	BB-156

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number - Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	U1	US- 6,291,245 B1	09-18-2001	Kopetzki et al.	ALL
	U2	US-			
	U3	US-			
	U4	US-			
	U5	US-			
	U6	US-			
	U7	US-			
	U8	US-			
	U9	US-			


FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
	F1	WO 01/60975 A	08-23-2001	Elitra Pharmaceuticals, Inc.	ALL	
	F2					
	F3					
	F4					
	F5					
	F6					
	F7					

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kind Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

**Complete if Known**

Application Number	10/551,658
Filing Date	September 30, 2005
First Named Inventor	Michael Gotthardt
Group Art Unit	Not yet assigned
Examiner Name	Not yet assigned
Attorney Docket Number	BB-156

Sheet 2 of 2

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	R1	BOCKAMP, E. <i>et al.</i> "Of Mice and Models: Improved Animal Models for Biomedical Research" <i>Physiological Genomics</i> , Jan. 20, 2003, pp. 115-132, Vol. 11.	
	R2	GANTOIS, I. <i>et al.</i> "Restoring the Phenotype of Fragile X Syndrome: Insight from the Mouse Model" <i>Current Molecular Medicine</i> , September 2001, pp. 447-455, Vol. 1, No. 4.	
	R3	GOTTHARDT, M. <i>et al.</i> "Conditional Expression of Mutant M-line Titins Results in Cardiomyopathy with Altered Sarcomere Structure" <i>Journal of Biological Chemistry</i> , Feb. 21, 2003, pp. 6059-6065, Vol. 278, No. 8.	
	R4	HAMILTON-WILLIAMS, E. <i>et al.</i> "Transgenic Rescue Implicates Beta2-Microglobulin as a Diabetes Susceptibility Gene in Nonobese Diabetic (NOD) Mice" <i>Proceedings of the National Academy of Sciences of the United States</i> , Sept. 25, 2001, pp. 11533-11538, Vol. 98, No. 20.	
	R5	KWAN, K. "Conditional Alleles in Mice: Practical Considerations for Tissue-specific Knockouts" <i>Genesis the Journal of Genetics and Development</i> , February 2002, pp. 49-62, Vol. 32, No. 2.	
	R6	MONAMI, U. <i>et al.</i> "A Transgene Carrying an A2G Missense Mutation in the SMN Gene Modulates Phenotypic Severity in Mice with Severe (Type 1) Spinal Muscular Atrophy" <i>Journal of Cell Biology</i> , Jan. 6, 2003, pp. 41-52, Vol. 160, No. 1.	
	R7	POOK, M. <i>et al.</i> "Rescue of the Friedreich's Ataxia Knockout Mouse by Human YAC Transgenesis" <i>Neurogenetics</i> , October 2001, pp. 185-193, Vol. 3, No. 4.	
	R8	TUVESON, D. <i>et al.</i> "Technologically Advanced Cancer Modeling in Mice" <i>Current Opinion in Genetics &amp; Development</i> , February 2002, pp. 105-110, Vol. 12, No. 1.	
	R9	WUTZ, A. <i>et al.</i> "Non-Imprinted Igf2r Expression Decreases Growth and Rescues the Tme Mutation in Mice" <i>Development</i> , May 2001, pp. 1881-1887, Vol. 128, No. 10.	
	R10		
	R11		
	R12		
	R13		

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.